Ganoderic acid DMCAS# 173075-45-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 173075-45-1 | SDF | Download SDF |
| PubChem ID | 11784642 | Appearance | Powder |
| Formula | C30H44O4 | M.Wt | 468.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (E,6R)-2-methyl-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3,7-dioxo-2,5,6,11,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-2-enoic acid | ||
| SMILES | CC(CCC=C(C)C(=O)O)C1CCC2(C1(CCC3=C2C(=O)CC4C3(CCC(=O)C4(C)C)C)C)C | ||
| Standard InChIKey | ZTKZZRIVAYGFSF-PIPDTRPPSA-N | ||
| Standard InChI | InChI=1S/C30H44O4/c1-18(9-8-10-19(2)26(33)34)20-11-16-30(7)25-21(12-15-29(20,30)6)28(5)14-13-24(32)27(3,4)23(28)17-22(25)31/h10,18,20,23H,8-9,11-17H2,1-7H3,(H,33,34)/b19-10+/t18-,20-,23+,28-,29-,30+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ganoderic acid DM is an antiandrogenic osteoclastogenesis inhibitor, it especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1), this suppression leads to the inhibition of dendritic cell-specific transmembrane protein (DC-STAMP) expression and reduces osteoclast fusion. Ganoderic acid DM has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease, it may an alternative agent for the treatment of advanced prostate cancer. |
| Targets | PARP | CDK | Androgen Receptor | 5-alpha Reductase | NF-kB | TNF-α |
| In vitro | Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells.[Pubmed: 22178684]Fitoterapia. 2012 Mar;83(2):408-14.Ganoderic acid DM (GADM) is a triterpenoid isolated from Ganoderma lucidum, a well-known edible medicinal mushroom. Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.[Pubmed: 24790681]Open Prost Cancer J. 2010 Jan 1;3:78-85.Prostate cancer is the most commonly diagnosed cancer in men and accounts for significant morbidity and mortality in the western world. While traditional therapies are effective at clearing early stage cancer, they often fail to treat late stage metastatic disease. Thus, an effective therapy that targets prostate tumor growth and metastasis is desired for alleviating the disease and improving patient outcomes. Natural extracts have been the focus of recent investigation, particularly those with reduced cellular toxicity to healthy tissue. In this review, we discuss one potential candidate, ganoderic acid, an extract from the Ganoderma lucidum mushroom that has been tested in multiple cancer models. Interestingly, Ganoderic acid DM (GA-DM) has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease. Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.[Pubmed: 19289282]Bioorg Med Chem Lett. 2009 Apr 15;19(8):2154-7.Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5alpha-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum, can inhibit prostate cancer cell growth and block osteoclastogenesis. |
| Cell Research | Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum.[Pubmed: 19026632 ]Eur J Pharmacol. 2009 Jan 5;602(1):1-7.
|
| Structure Identification | Sci Rep. 2012;2:905.Target proteins of ganoderic acid DM provides clues to various pharmacological mechanisms.[Pubmed: 23205267]Ganoderma fungus (Ganodermataceae) is a multifunctional medicinal mushroom and has been traditionally used for the treatment of various types of disease. Ganoderic acid DM (1) is a representative triterpenoid isolated from G. lingzhi and exhibits various biological activities. However, a universal starting point that triggers multiple signaling pathways and results in multifunctionality of 1 is unknown. |
Ganoderic acid DM Dilution Calculator
Ganoderic acid DM Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1336 mL | 10.6678 mL | 21.3356 mL | 42.6712 mL | 53.339 mL |
| 5 mM | 0.4267 mL | 2.1336 mL | 4.2671 mL | 8.5342 mL | 10.6678 mL |
| 10 mM | 0.2134 mL | 1.0668 mL | 2.1336 mL | 4.2671 mL | 5.3339 mL |
| 50 mM | 0.0427 mL | 0.2134 mL | 0.4267 mL | 0.8534 mL | 1.0668 mL |
| 100 mM | 0.0213 mL | 0.1067 mL | 0.2134 mL | 0.4267 mL | 0.5334 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Rhoifolin
Catalog No.:BCN1112
CAS No.:17306-46-6
- Rec 15/2615 dihydrochloride
Catalog No.:BCC7628
CAS No.:173059-17-1
- PMPA (NAALADase inhibitor)
Catalog No.:BCC2354
CAS No.:173039-10-6
- Goniothalamin
Catalog No.:BCN4690
CAS No.:17303-67-2
- Poloxime
Catalog No.:BCC5307
CAS No.:17302-61-3
- Isoanthricin
Catalog No.:BCN3531
CAS No.:17301-70-5
- BWX 46
Catalog No.:BCC5865
CAS No.:172997-92-1
- Biorobin
Catalog No.:BCN4691
CAS No.:17297-56-2
- FICZ
Catalog No.:BCC5513
CAS No.:172922-91-7
- PB 28 dihydrochloride
Catalog No.:BCC7411
CAS No.:172907-03-8
- Isosinensetin
Catalog No.:BCN2919
CAS No.:17290-70-9
- LY 266097 hydrochloride
Catalog No.:BCC7856
CAS No.:172895-39-5
- Centaureidin
Catalog No.:BCN2575
CAS No.:17313-52-9
- SQ 22536
Catalog No.:BCC7065
CAS No.:17318-31-9
- 4-Beta-Hydroxycholesterol
Catalog No.:BCN2752
CAS No.:17320-10-4
- Clomipramine HCl
Catalog No.:BCC5036
CAS No.:17321-77-6
- Broussonetine A
Catalog No.:BCN2515
CAS No.:173220-07-0
- 2,5-Dihydroxy-1-methoxyxanthone
Catalog No.:BCN7577
CAS No.:173220-32-1
- TC-E 5003
Catalog No.:BCC8008
CAS No.:17328-16-4
- Garciniaxanthone E
Catalog No.:BCN1114
CAS No.:173294-74-1
- Isorhamnetin 3-glucoside-7-rhamnoside
Catalog No.:BCN1528
CAS No.:17331-71-4
- Aliskiren
Catalog No.:BCC1338
CAS No.:173334-57-1
- Aliskiren Hemifumarate
Catalog No.:BCC5018
CAS No.:173334-58-2
- Pelargonidin-3,5-O-diglucoside chloride
Catalog No.:BCN1527
CAS No.:17334-58-6
Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.[Pubmed:24790681]
Open Prost Cancer J. 2010 Jan 1;3:78-85.
Prostate cancer is the most commonly diagnosed cancer in men and accounts for significant morbidity and mortality in the western world. While traditional therapies are effective at clearing early stage cancer, they often fail to treat late stage metastatic disease. Thus, an effective therapy that targets prostate tumor growth and metastasis is desired for alleviating the disease and improving patient outcomes. Natural extracts have been the focus of recent investigation, particularly those with reduced cellular toxicity to healthy tissue. In this review, we discuss one potential candidate, ganoderic acid, an extract from the Ganoderma lucidum mushroom that has been tested in multiple cancer models. Interestingly, Ganoderic acid DM (GA-DM) has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease. This review will discuss the current knowledge on this GA-DM extract and the potential benefit in treating advanced prostate cancer. We will also provide an overview on the targeted delivery of GA-DM through nanoparticles that would reduce bystander toxicity and improve the drug's effectiveness. An improved understanding of this drug and its uses will advance the field of natural chemotherapeutics, particularly in treating advanced prostate cancer.
Target proteins of ganoderic acid DM provides clues to various pharmacological mechanisms.[Pubmed:23205267]
Sci Rep. 2012;2:905.
Ganoderma fungus (Ganodermataceae) is a multifunctional medicinal mushroom and has been traditionally used for the treatment of various types of disease. Ganoderic acid DM (1) is a representative triterpenoid isolated from G. lingzhi and exhibits various biological activities. However, a universal starting point that triggers multiple signaling pathways and results in multifunctionality of 1 is unknown. Here we demonstrate the important clues regarding the mechanisms underlying multi-medicinal action of 1. We examined structure-activity relationships between 1 and its analogs and found that the carbonyl group at C-3 was essential for cytotoxicity. Subsequently, we used 1-conjugated magnetic beads as a probe and identified tubulin as a specific 1-binding protein. Furthermore, 1 showed a similar Kd to that of vinblastine and also affected assembly of tubulin polymers. This study revealed multiple biological activities of 1 and may contribute to the design and development of new tubulin-inhibiting agents.
Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells.[Pubmed:22178684]
Fitoterapia. 2012 Mar;83(2):408-14.
Ganoderic acid DM (GADM) is a triterpenoid isolated from Ganoderma lucidum, a well-known edible medicinal mushroom. In the present study, we found that GADM effectively inhibited cell proliferation and colony formation in MCF-7 human breast cancer cells, which was much stronger than that of MDA-MB-231 breast cancer cells. GADM both concentration- and time-dependently mediated G1 cell cycle arrest and significantly decreased the protein level of CDK2, CDK6, cycle D1, p-Rb and c-Myc in MCF-7 cells. Moreover, GADM obviously induced DNA fragmentation and cleavage of PARP which are the characteristics of apoptosis and decreased the mitochondrial membrane potential in MCF-7 cells. Besides, we also showed that GADM elicited DNA damage as measured by comet assay which is a sensitive method for DNA damage detection. gamma-H2AX, a marker of DNA damage, was also slightly up-regulated after treated with GADM for 6h, suggesting that the G1 cell cycle arrest and apoptosis induced by GADM may be partially resulted from GADM-induced DNA damage. These results have advanced our current understandings of the anti-cancer mechanisms of GADM.
Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum.[Pubmed:19026632]
Eur J Pharmacol. 2009 Jan 5;602(1):1-7.
The preventative effects of the ethanol extracts of Ganoderma lucidum against the ovariectomized (Ovx)-induced deterioration of bone density in 11-week-old female Sprague Dawley (SD) rats were investigated. The results showed that the G. lucidum-treated Ovx rats showed improved bone density compared with the Ovx rats. We studied the effects of G. lucidum on osteoclastic differentiation using bone marrow cells and RAW 264 cell D-clone (RAW-D). Differentiation, in response to receptor activator of NF-kappaB ligand (RANKL) and a tumor necrosis factor alpha (TNF-alpha), was inhibited by the ethanol extracts of G. lucidum and Ganoderic acid DM which was isolated as one of the active compounds by bioassay-guided fractionation. Ganoderic acid DM especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1). This suppression leads to the inhibition of dendritic cell-specific transmembrane protein (DC-STAMP) expression and reduces osteoclast fusion.
Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.[Pubmed:19289282]
Bioorg Med Chem Lett. 2009 Apr 15;19(8):2154-7.
Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5alpha-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum, can inhibit prostate cancer cell growth and block osteoclastogenesis.
